Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment

Results from the latest phase 3 clinical trial testing combinations of immunotherapy and tyrosine-kinase inhibitors for advanced kidney cancer improve standard first-line treatment options for patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Treatments for kidney cancer.


  1. Motzer, R.J. et al. N. Engl. J. Med. (2021).

  2. Choueiri, T. K. & Motzer, R. J. N. Engl. J. Med. 376, 354–366 (2017).

    CAS  Article  Google Scholar 

  3. Motzer, R. J. et al. N. Engl. J. Med. 369, 722–731 (2013).

    CAS  Article  Google Scholar 

  4. Chen, D. S. & Mellman, I. Nature 541, 321–330 (2017).

    CAS  Article  Google Scholar 

  5. Albiges, L. et al. ESMO Open 5, e001079 (2020).

    Article  Google Scholar 

  6. Powles, T. et al. Lancet Oncol 21, 1563–1573 (2020).

    CAS  Article  Google Scholar 

  7. Choueiri, T. K. et al. Ann. Oncol. 31, 1030–1039 (2020).

    CAS  Article  Google Scholar 

  8. Choueiri, T. K. et al. N. Engl. J. Med 384, 829–841 (2021).

    CAS  Article  Google Scholar 

  9. Pal, S. K. et al. Lancet 397, 695–703 (2021).

    CAS  Article  Google Scholar 

  10. Pal, S. K. et al. BMC Cancer 19, 548 (2019).

    Article  Google Scholar 

  11. Cho, H. et al. Nature 539, 107–111 (2016).

    CAS  Article  Google Scholar 

  12. Chen, W. et al. Nature 539, 112–117 (2016).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Tian Zhang.

Ethics declarations

Competing interests

T.Z. has received research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas and Regeneron; has received consulting/speaking fees from Genentech Roche, Exelixis, Genomic Health and Sanofi Aventis; reports serving on an advisory board and/or consulting for AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, MJH Associates, Merck, BMS, Pharmacyclics, Seattle Genetics, Calithera and Dendreon; and reports stock ownership and/or employment (spouse) with Capio Biosciences and Archimmune Therapeutics. D.J.G. has received research support (to Duke) from Acerta, Astellas, BMS, Bayer, Calithera, Exelixis, Janssen, Myovant, Pfizer, Novartis and Sanofi Aventis; and consulting fees from Vizuri Health sciences, UroToday, Sanofi, Pfizer, Nektar, Myovant, Modra, Merck, Ipsen, Flatiron, Exelixis, Capio, EMD Serono, BMS, Bayer, AstraZeneca and Astellas.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., George, D.J. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nat Med 27, 586–588 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer